“The Alzheimer’s Plan”: CFS/ME Patients Seek “Loosening” Of Approval Requirements
Executive Summary
FDA’s recent guidance on drug development in early-stage Alzheimer’s did not change the standard of evidence required for approval, agency official says amid calls to ease requirements for chronic fatigue syndrome/myalgic encephalomyelitis.